Menu

High Prevalence of Abnormal Anthropometrics in Lean Metabolic Dysfunction-Associated Steatotic Liver Disease: A National Cross-Sectional Study.

Gastroenterology · 1 Nov 2026 · Journal Article · Open access

Elhence, Harroun + more

Abstract ↗AI summary

The abstract is read at the publisher; the summary is JClub's.

There's no AI summary of this paper here yet.

Open it in JClub →

Open access

Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial.
The lancet. Gastroenterology & hepatology · 1 Sept 2026 · Randomized Controlled Trial
AI summary · may contain errors
In adults with metabolic dysfunction-associated steatohepatitis and F2–F4c fibrosis, zalfermin 30 mg plus semaglutide 2·4 mg did not significantly improve NASH CRN fibrosis by week 52 versus placebo (24% vs 16%).
- Open access
- 6 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42456707
Open in JClub

Journals this month

All journals →

Topics moving, week to 8 Nov 2026

By field

All journals by field →